Icon (NASDAQ:ICLR) had its price objective increased by Mizuho from $154.00 to $160.00 in a research report report published on Tuesday morning, The Fly reports. The brokerage currently has a buy rating on the medical research company’s stock.
ICLR has been the subject of a number of other reports. BidaskClub downgraded Icon from a hold rating to a sell rating in a research note on Saturday, April 13th. ValuEngine raised Icon from a hold rating to a buy rating in a research note on Friday, May 3rd. Zacks Investment Research raised Icon from a hold rating to a buy rating and set a $146.00 target price for the company in a research note on Wednesday, April 24th. Barclays increased their target price on Icon from $140.00 to $148.00 and gave the stock an equal weight rating in a research note on Monday, March 18th. Finally, Wolfe Research initiated coverage on Icon in a research note on Tuesday, April 2nd. They set an outperform rating for the company. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. Icon has an average rating of Buy and an average target price of $155.11.
Shares of ICLR stock opened at $145.04 on Tuesday. The company has a market cap of $7.71 billion, a PE ratio of 22.66, a price-to-earnings-growth ratio of 1.96 and a beta of 0.55. Icon has a 12-month low of $118.10 and a 12-month high of $155.33. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.30.
Icon (NASDAQ:ICLR) last issued its earnings results on Wednesday, May 1st. The medical research company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.03. The business had revenue of $674.85 million during the quarter, compared to the consensus estimate of $668.93 million. Icon had a return on equity of 25.71% and a net margin of 12.56%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.44 EPS. On average, equities research analysts expect that Icon will post 6.87 earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Truehand Inc purchased a new position in Icon in the 4th quarter valued at approximately $54,000. Benjamin F. Edwards & Company Inc. increased its stake in Icon by 36.6% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 116 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new position in Icon in the 4th quarter valued at approximately $64,000. Cresset Asset Management LLC purchased a new position in Icon in the 1st quarter valued at approximately $115,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in Icon in the 4th quarter valued at approximately $132,000. 85.75% of the stock is owned by hedge funds and other institutional investors.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Story: What is the Current Ratio?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.